EP2363130
Samsetning af HMG-CoA redúktasa tálma atoravastatín eða símvastatín með fosfódíesteresa 4 tálma, eins og roflúmílast til meðhöndlunar á lungnabólgusjúkdómum
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
3.7.2007EP published:
7.5.2014EP application number:
11164518.0
EP translation filed:
28.8.2014Grant published:
15.9.2014EPO information:
European Patent Register
Max expiry date:
2.7.2027Expiry date:
2.7.2020
Title:
Combination of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases
Timeline
Today
3.7.2007EP application
7.5.2014EP Publication
28.8.2014Translation submitted
15.9.2014Registration published
2.7.2020Expires
Owner
Name:
AstraZeneca ABAddress:
SE 151 85, , Södertälje, SE
Inventor
Name:
Wollin, Stefan-LutzAddress:
Bad Waldsee, DE
Name:
Wohlsen, AndreaAddress:
Bonn, DE
Name:
Braun, ClemensAddress:
Biberach, DE
Name:
Marx, DegenhardAddress:
Moos, DE
Agent
Name:
Reynaldsson Patent ConsultingAddress:
Pósthólf 48, 212, Garðabæ,
Priority
Number:
06116625Date:
5.7.2006Country:
EP
Classification
Categories:
A61K 31/44, A61K 31/277, A61K 31/4439, A61K 31/437, A61K 31/343, A61K 31/502, A61K 31/366, A61K 31/22, A61K 31/40, A61K 31/405, A61K 31/505, A61K 31/352, A61K 31/453, A61P 11/00, A61K 45/06
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 8.7.2014
Expires: 2.7.2015
Payer: Árnason Faktor
Number: 9
Paid: 9.6.2015
Expires: 2.7.2016
Payer: Árnason Faktor
Number: 10
Paid: 8.6.2016
Expires: 2.7.2017
Payer: Árnason Faktor
Number: 11
Paid: 7.6.2017
Expires: 2.7.2018
Payer: Árnason Faktor
Number: 12
Paid: 7.6.2018
Expires: 2.7.2019
Payer: Árnason Faktor
Number: 13
Paid: 5.6.2019
Expires: 2.7.2020
Payer: Árnason Faktor